GlassScriptPhysician profile
Neha Patel
NPI 1649208273
$8,142.25
in general payments reported to CMS, 2019-2025
24 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2022: $1,192 · 2023: $3,652 · 2024: $2,447 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,479 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,479.28 |
| Education | $101.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,941.05 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,851.90 | 2022-2024 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $774.36 | 2022-2024 | Xarelto |
| Novo Nordisk INC | $638.36 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $309.55 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Medtronic, INC. | $305.42 | 2023 | Hawkone, Signia |
| Exelixis INC. | $260.00 | 2019 | |
| Astellas Pharma US INC | $165.44 | 2022-2024 | Veozah |
| Inari Medical, INC. | $132.50 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Optinose US, INC. | $117.37 | 2023 | |
| Avadel Cns Pharmaceuticals, LLC | $116.49 | 2025 | Lumryz |
| Exact Sciences Corporation | $114.57 | 2023-2024 | Cologuard Collection Kit |
| Harmony Biosciences LLC | $111.31 | 2025 | |
| Abbvie INC. | $58.40 | 2022-2024 | |
| Horizon Therapeutics Plc | $56.38 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $40.57 | 2022 | |
| Dexcom, INC. | $35.40 | 2023-2024 | Dexcom G6 Transmitter |
| Verona Pharma, INC. | $18.14 | 2025 | Ohtuvayre |
| Dynavax Technologies Corporation | $17.74 | 2024 | Heplisav-B |
| Adma Biomanufacturing LLC | $17.43 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.87 | 2023 | Rexulti |
| Pfizer INC. | $15.69 | 2024 | |
| Phathom Pharmaceuticals, INC. | $14.25 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.